HiberCell, Inc. has acquired the Imprime PGG program from Biothera Pharmaceuticals, Inc.
This website will deactivate on August 31. To learn more visit HiberCell.com


Biothera Pharmaceuticals Presents Updated Phase 2 Data for Chemo-refractory Triple Negative Breast Cancer Patients at San Antonio Breast Cancer Symposium

EAGAN, MN — December 11, 2019 — Biothera Pharmaceuticals, Inc. announced today that updated response and clinical benefit data from its ongoing Phase 2 study in chemo-refractory metastatic triple negative breast cancer (mTNBC) patients were presented during a Spotlight Session at the 2019 San Antonio Breast Cancer Symposium (SABCS). The study is evaluating Biothera’s Imprime PGG, a systemically delivered dectin receptor agonist that triggers anti-cancer...

Read More